Lip G Y, Lowe G D, Metcalfe M J, Rumley A, Dunn F G
Department of Cardiology, Stobhill General Hospital, Glasgow, Scotland.
Am J Cardiol. 1995 Sep 1;76(7):453-8. doi: 10.1016/s0002-9149(99)80129-5.
Cardiac impairment in patients is associated with intracardiac thrombus formation and thromboembolism. A high prothrombotic state may exist in such patients, and abnormalities in plasma markers of thrombogenesis may be indicative of such a state. The aim of this study was to determine the associations of left ventricular (LV) aneurysm formation and dysfunction with plasma fibrinogen, von Willebrand factor, and fibrin D-dimer, which are markers associated with thrombus formation (thrombogenesis) and to investigate the effects of warfarin given to patients with LV aneurysms on fibrinogen and D-dimer levels. A cross-sectional study of 112 patients with coronary artery disease was initially performed: 34 patients had normal LV function (group 1); 30 had LV dysfunction without aneurysm formation (group 2); 29 had LV aneurysms without anticoagulation (group 3a); and 19 patients had LV aneurysms with warfarin therapy (group 3b). Results were compared with 158 population controls from a random population sample. A longitudinal study of 10 patients given warfarin was also performed. In group 1, plasma fibrinogen (median difference 0.36 g/L; p = 0.0009) and von Willebrand factor (median difference 17 IU/dl; p = 0.04) were elevated, whereas plasma D-dimer levels (median difference 23.0 ng/ml; p = 0.001) were lower than those in population control subjects. There were no significant differences in plasma fibrinogen, von Willebrand factor, or D-dimer levels between groups 1 and 2. In group 3a, plasma fibrinogen was elevated when compared with group 1 (median difference 0.6 g/L; p = 0.0001), with a trend toward high von Willebrand factor levels.(ABSTRACT TRUNCATED AT 250 WORDS)
患者的心脏损害与心内血栓形成及血栓栓塞有关。此类患者可能存在高血栓形成倾向状态,而血栓形成的血浆标志物异常可能提示这种状态。本研究的目的是确定左心室(LV)动脉瘤形成和功能障碍与血浆纤维蛋白原、血管性血友病因子和纤维蛋白D - 二聚体之间的关联,这些都是与血栓形成(血栓发生)相关的标志物,并研究给予LV动脉瘤患者华法林对纤维蛋白原和D - 二聚体水平的影响。最初对112例冠心病患者进行了横断面研究:34例患者左心室功能正常(第1组);30例有左心室功能障碍但无动脉瘤形成(第2组);29例有左心室动脉瘤且未接受抗凝治疗(第3a组);19例有左心室动脉瘤且接受华法林治疗(第3b组)。将结果与来自随机人群样本的158名人群对照进行比较。还对10例接受华法林治疗的患者进行了纵向研究。在第1组中,血浆纤维蛋白原(中位数差异0.36 g/L;p = 0.0009)和血管性血友病因子(中位数差异17 IU/dl;p = 0.04)升高,而血浆D - 二聚体水平(中位数差异23.0 ng/ml;p = 0.001)低于人群对照受试者。第1组和第2组之间血浆纤维蛋白原、血管性血友病因子或D - 二聚体水平无显著差异。在第3a组中,与第1组相比血浆纤维蛋白原升高(中位数差异0.6 g/L;p = 0.0001),血管性血友病因子水平有升高趋势。(摘要截断于250字)